Magyar
Toggle navigation
Tudóstér
Magyar
Tudóstér
Keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Böngészés
Saját polc tartalma
(
0
)
Korábbi keresések
Összesen 1 találat.
#/oldal:
12
36
60
120
Rövid
Hosszú
MARC
Részletezés:
Rendezés:
Szerző növekvő
Szerző csökkenő
Cím növekvő
Cím csökkenő
Dátum növekvő
Dátum csökkenő
1.
001-es BibID:
BIBFORM119085
035-os BibID:
(WoS)000979722700001 (Scopus)85163178290
Első szerző:
Perros, Petros
Cím:
Hypothyroidism and Somatization : results from E-Mode Patient Self-Assessment of Thyroid Therapy, a Cross-Sectional, International Online Patient Survey / Petros Perros, Endre Vezekenyi Nagy, Enrico Papini, Christina Maria Van Der Feltz-Cornelis, Anthony Peter Weetman, Harriet Alexandra Hay, Juan Abad-Madroñero, Amy Johanna Tallett, Megan Bilas, Peter Lakwijk, Alan J. Poots, Laszlo Hegedűs
Dátum:
2023
ISSN:
1050-7256
Megjegyzések:
Background: Between 10% and 15% of hypothyroid patients experience persistent symptoms despite achieving biochemical euthyroidism. Unexplained persistent symptoms can be a sign of somatization. This is associated with distress and high health care resource use and can be classified as somatic symptom disorder (SSD). Prevalence rates for SSD differ depending on classification criteria and how they are ascertained, varying between 4% and 25%. As this has not been studied in hypothyroid patients before, the aim of this study was to document somatization in people with hypothyroidism and to explore associations with other patient charac- teristics and outcomes. Methods: Online, multinational cross-sectional survey of individuals with self-reported, treated hypothyroid- ism, which included the validated Patient Health Questionnaire-15 (PHQ-15) for assessment of somatization. Chi-squared tests with the Bonferroni correction were used to explore outcomes for respondents with a PHQ-15 score œ10 (probable somatic symptom disorder [pSSD]) versus a PHQ-15 score <10 (absence of SSD). Results: A total of 3915 responses were received, 3516 of which contained the valid PHQ-15 data (89.8%). The median score was 11.3 (range 0?30 [confidence interval 10.9?11.3]). The prevalence of pSSD was 58.6%. Associations were found between pSSD and young age ( p < 0.001), women ( p < 0.001), not working ( p < 0.001), having below average household income ( p < 0.001), being treated with levothyroxine (LT4) (rather than combination of LT4 and L-triiodothyronine [LT3], LT3 alone, or desiccated thyroid extract) ( p < 0.001), expression of the view that the thyroid medication taken did not control the symptoms of hypo- thyroidism well ( p < 0.001), and with number of comorbidities ( p < 0.001). pSSD was associated with re- spondent attribution of most PHQ-15 symptoms to the hypothyroidism or its treatment ( p < 0.001), dissatisfaction with care and treatment of hypothyroidism ( p < 0.001), a negative impact of hypothyroidism on daily living ( p < 0.001), and with anxiety and low mood/depression ( p < 0.001). Conclusions: This study demonstrates a high prevalence of pSSD among people with hypothyroidism and associations between pSSD and negative patient outcomes, including a tendency to attribute persistent symp- toms to hypothyroidism or its treatment. SSD may be an important determinant of dissatisfaction with treatment and care among some hypothyroid patients.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
hypothyroidism
somatization
questionnaire
survey
levothyroxine
L-triiodothyronine
Megjelenés:
Thyroid. - 33 : 8 (2023), p. 927-939. -
További szerzők:
Nagy Endre V. (1957-) (belgyógyász, endokrinológus)
Papini, Enrico
Feltz-Cornelis, Christina Maria Van Der
Weetman, Anthony Peter
Hay, Harriet Alexandra
Abad-Madronero, Juan
Tallett, Amy Johanna
Bilas, Megan
Lakwijk, Peter
Poots, Alan J.
Hegedüs László
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
Rekordok letöltése
1
Corvina könyvtári katalógus v8.2.27
© 2023
Monguz kft.
Minden jog fenntartva.